CenTauR: Toward a universal scale and masks for standardizing tau imaging studies
暂无分享,去创建一个
D. Minhas | C. Rowe | B. Lopresti | O. Hansson | J. Fripp | R. Weimer | V. Villemagne | P. Bourgeat | A. Leuzy | V. Doré | Aibl Research Group | H. Shimada | S. Bullich | A. Gogola | S. S. Bohorquez | Y. Takado | S. S. Sanabria Bohórquez | A. Stephens | N. Krishnadas | Alzheimer's Disease Neuroimaging Initiative | C. Rowe | V. Villemagne | K. Huang | A. Stephens | M. Higuchi | Kun Huang | M. Higuchi | R. Weimer | Makoto Higuchi
[1] Joanne S. Robertson,et al. Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer’s Disease , 2022, Journal of Alzheimer's disease : JAD.
[2] D. Minhas,et al. Direct Comparison of the Tau PET Tracers 18F-Flortaucipir and 18F-MK-6240 in Human Subjects , 2021, The Journal of Nuclear Medicine.
[3] Joanne S. Robertson,et al. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer’s Disease , 2021, Journal of Alzheimer's disease reports.
[4] Philip S. Insel,et al. A multicenter comparison of [18F]flortaucipir, [18F]RO948, and [18F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[5] Sterling C. Johnson,et al. Four distinct trajectories of tau deposition identified in Alzheimer’s disease , 2021, Nature Medicine.
[6] C. Rowe,et al. Relationship between amyloid and tau levels and its impact on tau spreading , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[7] Keith A. Johnson,et al. Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation , 2020, Neurology.
[8] D. Minhas,et al. What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies , 2020, The Journal of Nuclear Medicine.
[9] Muhammad Naveed Iqbal Qureshi,et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. , 2020, Brain : a journal of neurology.
[10] O. Hansson,et al. Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders , 2020, JAMA neurology.
[11] Val J Lowe,et al. Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.
[12] H. Braak,et al. To stage, or not to stage , 2019, Current Opinion in Neurobiology.
[13] Marc D. Normandin,et al. Evaluation of pharmacokinetic modeling strategies for in-vivo quantification of tau with the radiotracer [18F]MK6240 in human subjects , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[14] C. Rowe,et al. AUTOMATED REPORTING OF TAU PET QUANTIFICATION ON THE BRAIN SURFACE , 2019, Alzheimer's & Dementia.
[15] L. Dinkelborg,et al. Discovery and preclinical characterization of [18F]PI-2620, a next-generation tau PET tracer for the assessment of tau pathology in Alzheimer’s disease and other tauopathies , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[16] William J. Jagust,et al. Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span , 2019, The Journal of Nuclear Medicine.
[17] M. Mintun,et al. Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging. , 2019, Journal of Alzheimer's disease : JAD.
[18] B. Miller,et al. Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.
[19] D. Wong,et al. Evaluation of 18F-RO-948 PET for Quantitative Assessment of Tau Accumulation in the Human Brain , 2018, The Journal of Nuclear Medicine.
[20] Christopher G Schwarz,et al. Longitudinal tau PET in ageing and Alzheimer’s disease , 2018, Brain : a journal of neurology.
[21] M. Körner,et al. Identification of Three Novel Radiotracers for Imaging Aggregated Tau in Alzheimer's Disease with Positron Emission Tomography. , 2017, Journal of medicinal chemistry.
[22] M. Mintun,et al. Kinetic Modeling of the Tau PET Tracer 18F-AV-1451 in Human Healthy Volunteers and Alzheimer Disease Subjects , 2017, The Journal of Nuclear Medicine.
[23] W. Vanduffel,et al. Preclinical Evaluation of 18F-JNJ64349311, a Novel PET Tracer for Tau Imaging , 2017, The Journal of Nuclear Medicine.
[24] Clifford R. Jack,et al. Tau-PET uptake: Regional variation in average SUVR and impact of amyloid deposition , 2016, Alzheimer's & dementia.
[25] Talakad G. Lohith,et al. Discovery of 6-(Fluoro-(18)F)-3-(1H-pyrrolo[2,3-c]pyridin-1-yl)isoquinolin-5-amine ([(18)F]-MK-6240): A Positron Emission Tomography (PET) Imaging Agent for Quantification of Neurofibrillary Tangles (NFTs). , 2016, Journal of medicinal chemistry.
[26] Daniel R. Schonhaut,et al. PET Imaging of Tau Deposition in the Aging Human Brain , 2016, Neuron.
[27] Christopher C Rowe,et al. Tau imaging: early progress and future directions , 2015, The Lancet Neurology.
[28] Robert A. Koeppe,et al. The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET , 2015, Alzheimer's & Dementia.
[29] Allen F. Brooks,et al. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. , 2014, ACS chemical neuroscience.
[30] C. Rowe,et al. Predicting Alzheimer disease with β‐amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing , 2013, Annals of neurology.
[31] J. Trojanowski,et al. Imaging of Tau Pathology in a Tauopathy Mouse Model and in Alzheimer Patients Compared to Normal Controls , 2013, Neuron.
[32] Min-Ying Su,et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. , 2013, Journal of Alzheimer's disease : JAD.
[33] C. Jack,et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.
[34] Elizabeth C Mormino,et al. Not quite PIB-positive, not quite PIB-negative: Slight PIB elevations in elderly normal control subjects are biologically relevant , 2012, NeuroImage.
[35] W. Jagust. Amyloid imaging: liberal or conservative? Let the data decide. , 2011, Archives of neurology.
[36] R. Petersen,et al. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.
[37] S. Cullum. Dementia (2nd edn) , 2001, British Journal of Psychiatry.
[38] A. Delacourte,et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.
[39] M. Bobinski,et al. Frequency of Stages of Alzheimer-Related Lesions in Different Age Categories , 1997, Neurobiology of Aging.